Haemotology/Oncology Flashcards
Post transplant lymphoproliferative disease related to what medication
T-cell suppression (especially with tacrolimus) is associated with a higher risk
of PTLD.
How much iron in 250ml blood unit
250mg
Vincristine and vinblastine mechanism of action
Inhibit mitosis by binding tubulin (minimal myelosuppression) METAPHASE
(Asparginase stops rna into tubulin protein)
Doxorubicin and doaunorubicin mechanism of action
Stops DNA replication by inhibiting topoisomerase and is a DNA intercalator (inserts into DNA) G2 phase
(Antibiotic) and also free radical damage like bleomycin
Cyclophosphamide and platinum mechanism of action
alkalynisation of DNA
Forms DNA cross links leading to apoptosis
Also ifosfamide
Cause of short stature with cranio-spinal radiotherapy
Failure of spinal growth
Highest incidence of secondary malign
Hodgkin lymphoma (10% at 20y)
Diamond-Blackfananaemia
Ribosomal protein disease
Dysmorphic, short, cleft, thumbs weird
Under 1, isolated MACROCYTIC anaemia from marrow failure (therefore no retics )
Bone marrow with decreased erythroid precursors but normal marrow
cellularity
(TEC also low retics but normocytic)
Bone marrow dysfunction with pancreas insufficiency and growth failure ? Cause and uss finding
Fatty infiltrate pancreas
Shwachman syndrome
Tumour lysis syndrome mx
Hyperhydrate Allopurinol xanthine oxidase inhibitor Risk of xanthine nephropathy Rasburicase (0.2 mg/kg) Urate oxidase Contraindicated in G6PD deficiency Risk of rash, hemolysis, anaphylaxis, methemoglobinemia
Drugs associated with mucositis
Bleomycin, Daunomycin, Methotrexate, Mitozantrone, Thioguanine,
Thiotepa, Vinblastine, Idarubicin, Mercaptopurine, Melphalan, 5‐
Fluorouracil, Hydroxyurea, Doxorubicin.
No or minimal BM suppression with which drugs
Cisplatin Asparginase Dacarbazine Procarbazine mercaptopurine Mitomycin C Lomustine Melphalan New monoclonals thioguanine
Haemorrhaging cysitis is SE of which chemo agents
Alkylating agents: Cyclophosphamide / Ifosfamide
At risk groups for secondary malignancy
Radiation exposure: AML, sarcomas
Etoposide exposure: AML, sarcomas
Hodgkins: mantle field irradiation
Genetic predispositons: retinoblastoma, fanconi anaemia, TP53 et
Warm autoimmune haemolytic mx
Supportive with folic acid. Avoid transfusing if possible
Warm antibody mediated responds to steroids
Dyskeratosis congenita (zinsser-Cole-England syndrome)
One of the disorders associated with short telomeres (Flow
FISH test). Others include Hoyeral Hreidisson and n Revesz
Syndrome)
• Genes TERT, TERC
• Ectodermal dysplasia
• Diagnostic “triad’: dystrophic nails, oral leucoplakia, reticular
pigmentation
• May present with pulmonary or liver fibrosis
• SCT for marrow failure. High morbidity and mortality
• Long term screening for oral, naso-pharyngea, vulval cancers
HLH
Hyper inflammation
High TG and high ferritin classic
Mild haemophilia A and VWD management
DDAVP in most instances - Works by releasing endogenous FVIII
Transenamic acid
Term male infant notice to have prolonged oozing from heel prick
site. No family history of bleeding.
Normal platelet count, PT, APTT and fibrinogen
Family reassured and baby discharged.
Mother re-presents in two weeks because umbilical stump oozing.
diagnosis?
Factor 13 deficiency
Defects in fibrinogen
Medulloblastoma predisposed conditions
Gorlin syndrome (basal-cell carcinoma nevus syndrome)
– 3% children with MB
– PTCH pathway mutation
• Turcot’s Syndrome
– Mismatch repair cancer syndrome (Lynch, HNPCC)
– Brain tumour and colorectal polyposis/cancer
– Usually HGG’s or MB in childhood/adolescence
• Li-Fraumeni Syndrome
– TP53
– Bimodal peak <10 years and 20-40 years
– Astrocytomas»_space; MB
Medulloblastoma groups
Genetically defined subgroups
1. WNT-activated – monosomy 6, classic histology, excellent
outcome (EFS >90%)
2. SHH-activated – PTCH pathway, lateral tumours, nodular
desmoplastic, infants have excellent outcome, TP53 mutated
tumour have very poor prognosis
3. Non-WNT/non-SHH
Group 3 – MYC amplification, large cell anaplastic
histology (LCA), poor outcome
Group 4 – MYCN amplification, classic or LCA,
intermediate outcome
ATRT (atypical teratoid rhabdoid tumour
Poor prognosis
Supratentorial
• Highly malignant • Usually occurs before 2 years age • ~15% children <3 years with malignant CNS tumour • Short clinical history • Anywhere in brain and spine • Disseminated disease in 20% • Biallelic inactivation of SMARCB1 in majority
Ependymoma mx
Surgery and focal radiation
High grade glioma
Small round blue cell tumours
Recent discovery of driver
mutations in histone H3.3 and
chromatin remodeling genes in
HGG
Craniopharyngioma MRI findings
Suprasellar
Calcification
Cysts
TS cancer type
Subependymal giant cell astrocytomas (SEGAs ) in 5-20%
Juvenile Pilocystic astrocytoma mx
Observe
Common late effect after brain tumour
GH deficiency
AML related to which syndrome
Downs (<3y, better survival and ALL worse survival)
Familial RUNX1 mutations
Aplastic anaemia
Myelodysplastic syndrome
Myeloproliferative disorders
Extramedullary haematopoesis (skin) think..
AML
AML morphology
PB/ BM: Blasts >20%
• Larger blasts
• Nucleus: More irregular, prominent nucleoli
• Cytoplasm: Auer rods, granules
Myeloperoxidase in flow cytomegalovirus
CD numbers for B and T cell ALL
B = 19 T = 3
T call ALL overall higher risk and presentation WCC not related to risk
Which cancer has Reed-Sternberg cell
EBV associated
Hodgkin lymphoma
Radiotherapy in ewings or osteosarcoma
Ewings
Mets of wilms, ewings, osteosarcoma to
Lungs
What tumours can metastasise to marrow
Alveolar Rhabdomyosarcoma can spread to bone marrow
Ewings
Child with spinal cord compression or intractable diarrhea or opsoclonus/myoclonus = jumping eyes think of…
Neuroblastoma
Poor prognostic factors in neuroblastoma
Combineclinicalfeatures(Metastases,unresectable biguglyprimary,age>18mths arebad).
Andlabtests(histology,MYCNamplification 8-200+ even if local disease,11qmissingarebad).
Can neuroblastoma regress by itself
Yes
Diagnosis in baby: Blueberry nodules on baby rapidly followed by expanding liver and respiratory embarrassment
Neuroblastoma